Randomized, controlled trial of RheothRx (poloxamer 188) in patients with suspected acute myocardial infarction....

Area of Science:

• Cardiology
• Pharmacology

Background:

• Patients with acute myocardial infarction (AMI) ineligible for reperfusion therapy often have comorbidities and worse outcomes.
• This population represents a significant unmet need for effective treatments.

Purpose of the Study:

• To evaluate the efficacy of RheothRx, a hemorheologic agent, in reducing myocardial infarct size and improving left ventricular function.
• To assess the safety and effectiveness of RheothRx in patients with suspected AMI not eligible for reperfusion therapy.

Main Methods:

• A randomized, controlled trial comparing RheothRx to placebo in patients with suspected AMI.
• Patients were randomly assigned to receive RheothRx (n=97) or placebo (n=99).
• Infarct size and left ventricular ejection fraction were measured; mortality and adverse events were recorded.

Main Results:

• RheothRx did not significantly reduce myocardial infarct size (p=0.60).
• Left ventricular ejection fraction was lower in the RheothRx group (p=0.026).
• Acute renal dysfunction occurred more frequently in the RheothRx group (12% vs 2%, p=0.005), leading to trial discontinuation.

Conclusions:

• RheothRx did not decrease infarct size or improve outcomes in patients with AMI ineligible for reperfusion therapy.
• The hemorheologic agent was associated with increased renal dysfunction.
• Effective treatments for this patient group remain critical.